Beta 3 adrenoceptors were described in 1980. They increase lipolysis, oxidation of fats, expenditure of energy and the action of insulin. Hence they have been thought to be important target for the treatment of diabetes mellitus and obesity [de Souza CJ et al. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001;7:1433-49]. Beta 3 adrenoceptors are stimulated only at high concentration of catecholamines, inducing negative inotropic effect and act as protection from overstimulation by catecholamines [Xiaolin Niu et al, Cardioprotective Effect of Beta-3 Adrenergic Receptor Agonism. Role of Neuronal Nitric Oxide Synthase.J Am Coll Cardiol, 2012; 59:1979-1987].